Formulation and Specifications: Capsules: 4mg, 10mg
Indications: Combined with everolimus for the treatment of advanced renal cell carcinoma (RCC) that has failed or progressed on prior antiangiogenic therapy.
Rational Dosing Points:
1. The recommended dose is 18 mg orally combined with everolimus 5 mg orally once daily.
2. Avoid combining with potent CYP3A4 inducers.
3. The occurrence of adverse reactions needs to be closely monitored during drug administration. The most common adverse reactions (≥30%) in kidney cancer treatment are diarrhea, fatigue, bone and joint pain, loss of appetite, nausea, vomiting, stomatitis, hypertension, etc. Dose reduction, suspension or permanent discontinuation of the drug if necessary.
4. Dose reduction recommendation: Dose reduction in accordance with 18mg→14mg→10mg→8mg is required.
5. In patients with severe renal impairment and hepatic impairment, the dose of lenvatinib should be changed to 10mg.
6. Lenvatinib should be taken at regular times of the day, either on an empty stomach or with food. If a patient misses a dose and is unable to take it within 12 hours, there is no need to make up the dose and the next dose should be taken at the regular dosing time.